Logo image of SRTA

STRATA CRITICAL MEDICAL INC (SRTA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SRTA - US0926671043 - Common Stock

5.68 USD
-0.04 (-0.7%)
Last: 1/9/2026, 8:28:04 PM
5.68 USD
0 (0%)
After Hours: 1/9/2026, 8:28:04 PM
Fundamental Rating

3

Taking everything into account, SRTA scores 3 out of 10 in our fundamental rating. SRTA was compared to 0 industry peers in the Unkown industry. The financial health of SRTA is average, but there are quite some concerns on its profitability. While showing a medium growth rate, SRTA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SRTA had negative earnings in the past year.
SRTA had a negative operating cash flow in the past year.
In the past 5 years SRTA always reported negative net income.
SRTA had a negative operating cash flow in each of the past 5 years.
SRTA Yearly Net Income VS EBIT VS OCF VS FCFSRTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M -50M

1.2 Ratios

Industry RankSector Rank
ROA 12.05%
ROE 14.27%
ROIC N/A
ROA(3y)-12.68%
ROA(5y)-33.09%
ROE(3y)-15.39%
ROE(5y)-48.99%
ROIC(3y)N/A
ROIC(5y)N/A
SRTA Yearly ROA, ROE, ROICSRTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

In the last couple of years the Gross Margin of SRTA has grown nicely.
Industry RankSector Rank
OM N/A
PM (TTM) 17.65%
GM 23.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.59%
GM growth 5YN/A
SRTA Yearly Profit, Operating, Gross MarginsSRTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, SRTA has more shares outstanding
SRTA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for SRTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SRTA Yearly Shares OutstandingSRTA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
SRTA Yearly Total Debt VS Total AssetsSRTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 5.30 indicates that SRTA is not in any danger for bankruptcy at the moment.
There is no outstanding debt for SRTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.3
ROIC/WACCN/A
WACCN/A
SRTA Yearly LT Debt VS Equity VS FCFSRTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 4.39 indicates that SRTA has no problem at all paying its short term obligations.
A Quick Ratio of 4.39 indicates that SRTA has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 4.39
Quick Ratio 4.39
SRTA Yearly Current Assets VS Current LiabilitesSRTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 60.87% over the past year.
Looking at the last year, SRTA shows a decrease in Revenue. The Revenue has decreased by -5.40% in the last year.
SRTA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 70.13% yearly.
EPS 1Y (TTM)60.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y70.13%
Revenue growth 5YN/A
Sales Q2Q%-34.16%

3.2 Future

SRTA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.23% yearly.
The Revenue is expected to grow by 7.57% on average over the next years.
EPS Next Y58.65%
EPS Next 2Y35.96%
EPS Next 3Y24.23%
EPS Next 5YN/A
Revenue Next Year-12.66%
Revenue Next 2Y4.34%
Revenue Next 3Y7.57%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SRTA Yearly Revenue VS EstimatesSRTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
SRTA Yearly EPS VS EstimatesSRTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SRTA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SRTA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRTA Price Earnings VS Forward Price EarningsSRTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60 -80 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRTA Per share dataSRTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as SRTA's earnings are expected to grow with 24.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.96%
EPS Next 3Y24.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SRTA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

STRATA CRITICAL MEDICAL INC

NASDAQ:SRTA (1/9/2026, 8:28:04 PM)

After market: 5.68 0 (0%)

5.68

-0.04 (-0.7%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)03-11 2026-03-11/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change3.73%
Market Cap0
Revenue(TTM)228.76M
Net Income(TTM)40.39M
Analysts85
Price Target9.82 (72.89%)
Short Float %N/A
Short Ratio7.23
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-53.74%
Min EPS beat(2)-96.08%
Max EPS beat(2)-11.41%
EPS beat(4)1
Avg EPS beat(4)-16.86%
Min EPS beat(4)-96.08%
Max EPS beat(4)64.99%
EPS beat(8)3
Avg EPS beat(8)-46.19%
EPS beat(12)5
Avg EPS beat(12)-23.19%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)9.08%
Min Revenue beat(2)8.32%
Max Revenue beat(2)9.84%
Revenue beat(4)4
Avg Revenue beat(4)7.53%
Min Revenue beat(4)4.23%
Max Revenue beat(4)9.84%
Revenue beat(8)6
Avg Revenue beat(8)4.07%
Revenue beat(12)10
Avg Revenue beat(12)5.21%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.05%
PT rev (3m)22.87%
EPS NQ rev (1m)37.5%
EPS NQ rev (3m)28.57%
EPS NY rev (1m)-66.67%
EPS NY rev (3m)-36.36%
Revenue NQ rev (1m)-0.58%
Revenue NQ rev (3m)5.23%
Revenue NY rev (1m)14.51%
Revenue NY rev (3m)2.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.92
P/FCF N/A
P/OCF N/A
P/B 1.56
P/tB 2.96
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS2.95
BVpS3.65
TBVpS1.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 12.05%
ROE 14.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 17.65%
GM 23.78%
FCFM N/A
ROA(3y)-12.68%
ROA(5y)-33.09%
ROE(3y)-15.39%
ROE(5y)-48.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.59%
GM growth 5YN/A
F-Score3
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 209.44%
Cap/Sales 6.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.39
Quick Ratio 4.39
Altman-Z 5.3
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)198.6%
Cap/Depr(5y)143.5%
Cap/Sales(3y)4.9%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
EPS Next Y58.65%
EPS Next 2Y35.96%
EPS Next 3Y24.23%
EPS Next 5YN/A
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y70.13%
Revenue growth 5YN/A
Sales Q2Q%-34.16%
Revenue Next Year-12.66%
Revenue Next 2Y4.34%
Revenue Next 3Y7.57%
Revenue Next 5YN/A
EBIT growth 1Y56.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year138.06%
EBIT Next 3Y40.45%
EBIT Next 5YN/A
FCF growth 1Y-64.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.84%
OCF growth 3YN/A
OCF growth 5YN/A

STRATA CRITICAL MEDICAL INC / SRTA FAQ

What is the ChartMill fundamental rating of STRATA CRITICAL MEDICAL INC (SRTA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SRTA.


Can you provide the valuation status for STRATA CRITICAL MEDICAL INC?

ChartMill assigns a valuation rating of 1 / 10 to STRATA CRITICAL MEDICAL INC (SRTA). This can be considered as Overvalued.


What is the profitability of SRTA stock?

STRATA CRITICAL MEDICAL INC (SRTA) has a profitability rating of 1 / 10.


What is the financial health of STRATA CRITICAL MEDICAL INC (SRTA) stock?

The financial health rating of STRATA CRITICAL MEDICAL INC (SRTA) is 6 / 10.


What is the expected EPS growth for STRATA CRITICAL MEDICAL INC (SRTA) stock?

The Earnings per Share (EPS) of STRATA CRITICAL MEDICAL INC (SRTA) is expected to grow by 58.65% in the next year.